JP2005511605A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005511605A5 JP2005511605A5 JP2003542163A JP2003542163A JP2005511605A5 JP 2005511605 A5 JP2005511605 A5 JP 2005511605A5 JP 2003542163 A JP2003542163 A JP 2003542163A JP 2003542163 A JP2003542163 A JP 2003542163A JP 2005511605 A5 JP2005511605 A5 JP 2005511605A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- halogen
- aryl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 description 61
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 47
- 125000003710 aryl alkyl group Chemical group 0.000 description 40
- 125000003118 aryl group Chemical group 0.000 description 39
- 229910052736 halogen Inorganic materials 0.000 description 36
- 125000001424 substituent group Chemical group 0.000 description 34
- 125000003545 alkoxy group Chemical group 0.000 description 32
- 150000002367 halogens Chemical class 0.000 description 32
- 125000003282 alkyl amino group Chemical group 0.000 description 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 26
- 125000001072 heteroaryl group Chemical group 0.000 description 24
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 20
- 125000003107 substituted aryl group Chemical group 0.000 description 18
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 17
- 125000000753 cycloalkyl group Chemical group 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 11
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- -1 2,6-difluorophenyl Chemical group 0.000 description 6
- 102000004378 Melanocortin Receptors Human genes 0.000 description 6
- 108090000950 Melanocortin Receptors Proteins 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 125000004951 trihalomethoxy group Chemical group 0.000 description 6
- 125000004953 trihalomethyl group Chemical group 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 5
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000001548 androgenic effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000005415 substituted alkoxy group Chemical group 0.000 description 3
- XTHRTBCPBWJYRO-UHFFFAOYSA-N 2,3-bis(2-methoxyphenyl)-n-phenyl-1,2,4-thiadiazol-5-imine Chemical compound COC1=CC=CC=C1C(N(S1)C=2C(=CC=CC=2)OC)=NC1=NC1=CC=CC=C1 XTHRTBCPBWJYRO-UHFFFAOYSA-N 0.000 description 2
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 201000004700 rosacea Diseases 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 0 CC(N=C(*)N(C)S)=N Chemical compound CC(N=C(*)N(C)S)=N 0.000 description 1
- 206010050337 Cerumen impaction Diseases 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102000030612 Melanocortin 5 receptor Human genes 0.000 description 1
- 108010088565 Melanocortin 5 receptor Proteins 0.000 description 1
- 206010072139 Ocular rosacea Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 102000008318 Type 3 Melanocortin Receptor Human genes 0.000 description 1
- 108010021433 Type 3 Melanocortin Receptor Proteins 0.000 description 1
- 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 description 1
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000002939 cerumen Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000000804 eccrine gland Anatomy 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 210000004175 meibomian gland Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 208000020469 nerve plexus disease Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 201000006380 plexopathy Diseases 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33792701P | 2001-11-08 | 2001-11-08 | |
| PCT/US2002/035340 WO2003040117A1 (en) | 2001-11-08 | 2002-11-04 | Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005511605A JP2005511605A (ja) | 2005-04-28 |
| JP2005511605A5 true JP2005511605A5 (enExample) | 2006-01-05 |
| JP4436676B2 JP4436676B2 (ja) | 2010-03-24 |
Family
ID=23322615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003542163A Expired - Fee Related JP4436676B2 (ja) | 2001-11-08 | 2002-11-04 | メラノコルチン受容体調節剤としての新規な１，２，４−チアジアゾール誘導体 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7049331B2 (enExample) |
| EP (1) | EP1446394B1 (enExample) |
| JP (1) | JP4436676B2 (enExample) |
| CN (1) | CN1312139C (enExample) |
| AR (1) | AR037331A1 (enExample) |
| AT (1) | ATE344254T1 (enExample) |
| AU (1) | AU2009201842B2 (enExample) |
| BR (1) | BR0214024A (enExample) |
| CA (1) | CA2466140C (enExample) |
| CY (1) | CY1105907T1 (enExample) |
| DE (1) | DE60215848T2 (enExample) |
| DK (1) | DK1446394T3 (enExample) |
| ES (1) | ES2275918T3 (enExample) |
| IL (1) | IL161829A (enExample) |
| MX (1) | MXPA04004458A (enExample) |
| MY (1) | MY134993A (enExample) |
| NO (1) | NO328195B1 (enExample) |
| NZ (1) | NZ532883A (enExample) |
| PT (1) | PT1446394E (enExample) |
| RS (1) | RS51530B (enExample) |
| RU (1) | RU2317292C2 (enExample) |
| SG (1) | SG176310A1 (enExample) |
| SI (1) | SI1446394T1 (enExample) |
| TW (1) | TWI328586B (enExample) |
| WO (1) | WO2003040117A1 (enExample) |
| ZA (1) | ZA200404484B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7655658B2 (en) | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
| US7732451B2 (en) | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
| JP2005504043A (ja) | 2001-08-10 | 2005-02-10 | パラチン テクノロジーズ インク． | 生物学的に活性な金属ペプチド類のペプチド模倣体類 |
| US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
| US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
| US7319107B2 (en) * | 2001-11-08 | 2008-01-15 | Johnson & Johnson Consumer Companies, Inc. | 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
| EP1446394B1 (en) * | 2001-11-08 | 2006-11-02 | Ortho-McNeil Pharmaceutical, Inc. | Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators |
| US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
| US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
| US7968548B2 (en) * | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
| WO2005054849A2 (en) * | 2003-12-06 | 2005-06-16 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor mc5 (mc5r) |
| WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
| US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
| MXPA06012130A (es) * | 2004-04-20 | 2007-01-31 | Transtech Pharma Inc | Derivados de tiazol y pirimidina substituidos como moduladores del receptor de melanocortina. |
| CA2584806C (en) | 2004-11-01 | 2014-06-17 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
| EP2330125A3 (en) | 2005-08-11 | 2012-12-12 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
| AU2006279680B2 (en) | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
| US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
| US7704533B2 (en) * | 2006-12-13 | 2010-04-27 | J&J Consumer Companies, Inc. | Compositions and methods of inducing hair growth utilizing Continus coggygria |
| CA2672524C (en) * | 2006-12-14 | 2016-08-23 | Neuronova Ab | Treatment of disease or injury of the nervous system using agents that decrease the activity of the melanocortin 4 receptor |
| RU2348623C1 (ru) * | 2007-05-21 | 2009-03-10 | Государственное образовательное учреждение высшего профессионального образования "Ивановский государственный химико-технологический университет" (ИГХТУ) | Способ получения 3,5-диамино-1,2,4-тиадиазола |
| EP2278962B1 (en) | 2008-02-21 | 2014-02-12 | Janssen Pharmaceutica N.V. | Methods for the treatment of dermatological disorders |
| US8008291B2 (en) * | 2008-02-29 | 2011-08-30 | Mimetica Pty Ltd | 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists |
| US8343958B2 (en) | 2008-02-29 | 2013-01-01 | Mimetica Pty Ltd | 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists |
| US8377925B2 (en) | 2008-02-29 | 2013-02-19 | Mimetica Pty Ltd | Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor |
| JP2012501334A (ja) | 2008-08-29 | 2012-01-19 | トランス テック ファーマ，インコーポレイテッド | 置換アミノチアゾール誘導体、医薬組成物、および使用の方法 |
| EP2358200A4 (en) | 2008-11-17 | 2012-05-16 | Merck Sharp & Dohme | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES |
| WO2010124175A1 (en) * | 2009-04-24 | 2010-10-28 | Johnson & Johnson Consumer Companies, Inc. | Stable topical compositions for 1,2,4-thiadiazole derivatives |
| WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| WO2011011508A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| ES2360783B1 (es) * | 2009-10-02 | 2012-07-04 | Consejo Superior De Investigaciones Científicas (Csic) | 1,2,4-tiadiazoles-5-imino sustituidos utiles en el tratamiento de enfermedades neurodegenerativas |
| US8470880B2 (en) | 2009-12-15 | 2013-06-25 | Mcneil-Ppc, Inc. | Methods of reducing hair loss and/or facilitating hair growth and/or regrowth |
| US8470833B2 (en) | 2009-12-15 | 2013-06-25 | Mcneil-Ppc, Inc. | Hair growth and/or regrowth compositions |
| WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
| US9365539B2 (en) | 2010-05-11 | 2016-06-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
| WO2011156246A1 (en) | 2010-06-11 | 2011-12-15 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
| CA2825098C (en) | 2011-01-27 | 2020-03-10 | Universite De Montreal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
| DK2888010T3 (da) | 2012-08-22 | 2021-06-28 | Univ Cornell | Fremgangsmåder til at hæmme fascin |
| US8962041B2 (en) | 2013-02-12 | 2015-02-24 | Johnson & Johnson Consumer Companies, Inc. | Methods and compositions for enhancing hair quality using blackberry extract |
| DK3107902T3 (da) | 2014-02-20 | 2021-05-03 | Cornell Univ Cornell Center For Technology Enterprise & Commercialization Cctec | Forbindelser og fremgangsmåder til at hæmme fascin |
| WO2019241755A2 (en) * | 2018-06-15 | 2019-12-19 | Jay Dela Cruz | Treatment of synucleinopathy and animal models of synucleinopathy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE131373C (enExample) | ||||
| JPS6011481A (ja) | 1983-06-30 | 1985-01-21 | Nippon Soda Co Ltd | １，２，４−チアジアゾ−ル系誘導体及び農園芸用殺菌剤 |
| JPH02173165A (ja) | 1988-12-27 | 1990-07-04 | Nippon Soda Co Ltd | 防汚剤 |
| ID24231A (id) * | 1997-06-24 | 2000-07-13 | Janssen Pharmaceutica Nv | Derivat-derivat 5-disubstitusi-1,2,4-tiadiazolil yang menghambat angiogenesis |
| EP1076649A4 (en) | 1998-04-28 | 2010-06-02 | Trega Biosciences Inc | ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE |
| CN1111523C (zh) | 1998-04-29 | 2003-06-18 | 阿克西瓦有限公司 | 催化制备取代的联吡啶衍生物的方法 |
| US6294534B1 (en) * | 1998-06-11 | 2001-09-25 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| AU742425B2 (en) | 1998-06-11 | 2002-01-03 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| WO2000024725A1 (en) | 1998-10-26 | 2000-05-04 | Vertex Pharmaceuticals Incorporated | Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase |
| AU2001228681A1 (en) * | 2000-01-28 | 2001-08-07 | Melacure Therapeutics Ab | Novel aromatic amines and amides acting on the melanocortin receptors |
| EP1446394B1 (en) * | 2001-11-08 | 2006-11-02 | Ortho-McNeil Pharmaceutical, Inc. | Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators |
| US7319107B2 (en) * | 2001-11-08 | 2008-01-15 | Johnson & Johnson Consumer Companies, Inc. | 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
-
2002
- 2002-11-04 EP EP02776448A patent/EP1446394B1/en not_active Expired - Lifetime
- 2002-11-04 MX MXPA04004458A patent/MXPA04004458A/es active IP Right Grant
- 2002-11-04 DK DK02776448T patent/DK1446394T3/da active
- 2002-11-04 DE DE60215848T patent/DE60215848T2/de not_active Expired - Lifetime
- 2002-11-04 RS YUP-397/04A patent/RS51530B/sr unknown
- 2002-11-04 SI SI200230459T patent/SI1446394T1/sl unknown
- 2002-11-04 JP JP2003542163A patent/JP4436676B2/ja not_active Expired - Fee Related
- 2002-11-04 US US10/287,095 patent/US7049331B2/en not_active Expired - Fee Related
- 2002-11-04 ES ES02776448T patent/ES2275918T3/es not_active Expired - Lifetime
- 2002-11-04 NZ NZ532883A patent/NZ532883A/en not_active IP Right Cessation
- 2002-11-04 SG SG2006034359A patent/SG176310A1/en unknown
- 2002-11-04 WO PCT/US2002/035340 patent/WO2003040117A1/en not_active Ceased
- 2002-11-04 BR BR0214024-1A patent/BR0214024A/pt active Search and Examination
- 2002-11-04 PT PT02776448T patent/PT1446394E/pt unknown
- 2002-11-04 CA CA2466140A patent/CA2466140C/en not_active Expired - Fee Related
- 2002-11-04 AT AT02776448T patent/ATE344254T1/de active
- 2002-11-04 RU RU2004114214/04A patent/RU2317292C2/ru not_active IP Right Cessation
- 2002-11-04 CN CNB028268547A patent/CN1312139C/zh not_active Expired - Fee Related
- 2002-11-07 AR ARP020104272A patent/AR037331A1/es not_active Application Discontinuation
- 2002-11-08 MY MYPI20024179A patent/MY134993A/en unknown
- 2002-11-08 TW TW091133320A patent/TWI328586B/zh not_active IP Right Cessation
-
2004
- 2004-05-06 IL IL161829A patent/IL161829A/en not_active IP Right Cessation
- 2004-06-07 NO NO20042372A patent/NO328195B1/no not_active IP Right Cessation
- 2004-06-07 ZA ZA2004/04484A patent/ZA200404484B/en unknown
-
2006
- 2006-02-01 US US11/344,772 patent/US7375123B2/en not_active Expired - Fee Related
-
2007
- 2007-01-08 CY CY20071100017T patent/CY1105907T1/el unknown
-
2009
- 2009-05-08 AU AU2009201842A patent/AU2009201842B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005511605A5 (enExample) | ||
| JP2005511606A5 (enExample) | ||
| CA2466140A1 (en) | Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators | |
| RU2004114208A (ru) | Новые производные 1, 2, 4-тиадиазолия в каестве модуляторов рецепторов меланокортина | |
| RU2374239C2 (ru) | Производные арилпиридина | |
| RU2435757C2 (ru) | Производные 3-циклил-2-(4-сульфамоилфенил)-n-циклилпропионамида, применимые для лечения нарушенной переносимости глюкозы и диабета | |
| TWI287984B (en) | Pharmaceutical composition for modulating bladder function | |
| KR890005069A (ko) | 치환된 1-[아르알킬- 피페라지노알킬]사이클로알칸올 | |
| JP2004512328A5 (enExample) | ||
| RU99105567A (ru) | Производные пропионовой кислоты и их использование | |
| US20060014781A1 (en) | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | |
| KR960014125A (ko) | 헤테로사이클 화합물, 이들의 제조방법 및 용도 | |
| RU2008104919A (ru) | Производные оксимов и их получение | |
| CA2402991A1 (en) | Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases | |
| JP2007533722A5 (enExample) | ||
| JP2003506354A5 (enExample) | ||
| WO2008143254A1 (ja) | ＰＰＡＲδアゴニスト含有医薬 | |
| US20210283128A1 (en) | Methods for treating or limiting development of cardiovascular disease-related neurological disorders | |
| JP2006516251A5 (enExample) | ||
| CN1300210A (zh) | 作为抗菌剂的异羟肟酸衍生物 | |
| JP2006511446A5 (enExample) | ||
| WO2001030749B1 (en) | Novel compounds | |
| WO2006094763A8 (en) | 3,4,5-substituted piperidine compounds | |
| JP2004520329A5 (enExample) | ||
| US20180344692A1 (en) | Methods of treating alpha adrenergic mediated conditions |